iShares Global Tech ETF vs GeneDx Holdings Corp — how do they compare? iShares Global Tech ETF trades at $142.15, while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: iShares Global Tech ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| IXN | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $149.74 | $167.51 |
52-Week Low | $94.42 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
IXN trades at $142.54, up 2.24% with strong technical momentum as moving averages signal bullish sentiment. The ETF shows robust technical positioning near resistance levels while maintaining neutral oscillator readings. Recent dividend activity and global tech exposure highlight its investment profile.
Outlook remains cautiously optimistic given high valuations and concentration risks in tech holdings. Key opportunities include AI-driven growth exposure, while risks involve stretched valuations and sector volatility. Analyst consensus suggests holding for strategic tech allocation.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Trailing returns across standard periods
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →